Momelotinib (also known as CYT387, a JAK1/2 inhibitor) showed favorable therapeutic effects on myelofibrosis in preclinical trials by reducing multiple myeloma proliferation, inducing apoptosis of JAK2-dependent haematopoietic cells, and regulating inflammatory cytokines303. Here, JAK1 is linked to myelofibrosis.